Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charlie Hospital Semarang Tbk. (RSCH) vs Unilever Indonesia Tbk. (UNVR) Price & Performance

Charlie Hospital Semarang Tbk.Trade
Unilever Indonesia Tbk.Trade

Price performance (Past 24H)

Key statistics

Charlie Hospital Semarang Tbk. vs Unilever Indonesia Tbk. — how do they compare? Charlie Hospital Semarang Tbk. trades at Rp270 (market cap 742B, 29.45M 24h volume), while Unilever Indonesia Tbk. trades at Rp1,710 (market cap 66.19T, 17.49M 24h volume). The key difference: Unilever Indonesia Tbk. is far larger — about 89.2× Charlie Hospital Semarang Tbk.'s market cap, and Charlie Hospital Semarang Tbk. is more actively traded (29.45M versus 17.49M). Which is the better fit depends on your goals.

RSCHUNVR
Market Cap
742B66.19T
Volume
29.45M17.49M
Lot
294.49K174.92K
Turnover
8.14B30.1B
Average Price
276.351,720.92
Value
8.14B30.1B
Indicative Equilibrium Price
2701,710
Indicative Equilibrium Volume
10313.43K

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

RSCH
View details
UNVR
View details

About Charlie Hospital Semarang Tbk.

PT Charlie Hospital Semarang, Tbk (the "Company") was established based on Deed No. 35 dated 11 February 2019, which was made before Notary Nur Hadi, SH, MKn, notary in Kendal Regency and has been approved by the Minister of Law and Human Rights of the Republic of Indonesia based on Decree No. AHU-0008598.AH.01.01. Year 2019 February 11, 2019. The company started its commercial operations on September 23, 2019.

Read more on RSCH

About Unilever Indonesia Tbk.

PT Unilever Indonesia Tbk (the Company) was established on 5 December 1933 as Levers Zeepfabrieken N.V. by deed No. 23 of Mr. A.H. van Ophuijsen, a notary in Batavia, which was approved by the Gouverneur Generaal van Nederlandsch-Indie in letter No. 14 on 16 December 1933, registered at the Raad van Justitie in Batavia under No. 302 on 22 December 1933 and published in the Javasche Courant on 9 January 1934, Supplement No. 3.

Read more on UNVR